Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Read more
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company SHANGHAI, China, May 26, 2020…